JACC. Heart failureHumansHeart FailureDouble-Blind MethodMaleFemale
Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of CRD-740, a PDE9 Inhibitor, in Chronic Heart Failure.
James E Udelson, Jan Bělohlávek, Andrej Dukát, Justin Ezekowitz, Sorel Goland, Bela Merkely, Eileen O'Meara, Mark C Petrie, Piotr Ponikowski, Michele Senni, Mariya Tokmakova, Orly Vardeny, Brian Claggett, Elizabeth Moore, Meghan Savard
Published: 202610.1016/j.jchf.2025.102706
Abstract
BACKGROUND: The beneficial effects of natriuretic peptide receptor activation are mediated by cyclic guanosine monophosphate (cGMP). Phosphodiesterase 9 (PDE9) hydrolyzes cGMP and therefore its inhibition has the potential to increase intracellular c…
Preview only. Read the full abstract at the source